

Wyeth Pakistan Limited

S-33, Hawkes Bay Road, S.I.T.E.

Karachi - 75730 Pakistan

Tel: +92 (21)-32354651-60

Fax: +92 (21)-32354681

Wyeth®

Ref. No.: Fin.073

May 22, 2017

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Subject : Disclosure of Material Information – Signing of Transaction Agreements


Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following:

In relation to the sale of the manufacturing facility owned by Wyeth Pakistan Limited ('**Wyeth**'), located at S-33, Hawkes Bay Road, S.I.T.E. Karachi, along with sale of (i) Wyeth's non-core products and registrations, consisting of Entox-P; Lederplex; Lederrif; Mucaine; Nilstat; Tri-Hemic; and Wymox, and (ii) Pfizer Pakistan Limited's products and registration, namely Citralka and Combantrin (together as "**the Assets**"), we hereby inform you that ICI Pakistan Limited (as the '**Purchaser**') and each of Wyeth, Pfizer Pakistan Limited, Pfizer Inc., and Wyeth LLC (as '**Sellers**') have entered into the Asset Purchase Agreements each dated as of May 19, 2017, recording terms and conditions for the proposed sale of the Assets by the Sellers and its acquisition by the Purchaser (**APAs**), at an aggregate purchase price of PKR 1.91 billion (of which PKR 1.68 billion is attributable to Wyeth Pakistan Limited). The completion of the transaction contemplated in the APAs will remain subject to satisfaction of conditions precedent and regulatory and shareholders approvals specified therein.

A disclosure form as required under S.R.O.143(1)/2012 dated December 5, 2012 read with Section 131 of the Securities Act, 2015 is also enclosed as **Annexure – 'A'**.

Sincerely,



Kashif Shafi
Company Secretary

CC : The Commissioner
Company Law Division, Securities & Exchange Commission of Pakistan
NIC Building, Jinnah Avenue, Islamabad.

The Commissioner
Securities Market Division, Securities & Exchange Commission of Pakistan
NIC Building, Jinnah Avenue, Islamabad.

Wyeth Pakistan Limited

S-33, Hawkes Bay Road, S.I.T.E.

Karachi - 75730 Pakistan

Tel: +92 (21)-32354651-60

Fax: +92 (21)-32354681

Wyeth®**Annexure – 'A'****DISCLOSURE FORM****IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015**

Name of Company:	Wyeth Pakistan Limited S-33, Hawkes Bay Road, S.I.T.E. Karachi
Date of Report:	May 22, 2017
Contact Information:	Dr. Farid Khan Chief Executive Telephone Number: +92 21-32200121(5 Lines) Fax Number: +92 21-32204454, 32331045 Email Address: info@wyethpakistan.com

☒ Public disclosure of price sensitive / inside information, which directly concerns the listed securities.

Disclosure of price sensitive / inside information by listed company.

In relation to the sale of the manufacturing facility owned by Wyeth Pakistan Limited ('**Wyeth**'), located at S-33, Hawkes Bay Road, S.I.T.E. Karachi, along with sale of (i) Wyeth's non-core products and registrations, consisting of Entox-P; Lederplex; Lederriif; Mucaine; Nilstat; Tri-Hemic; and Wymox, and (ii) Pfizer Pakistan Limited's products and registration, namely Citralka and Combantrin (together as "**the Assets**"), we hereby inform you that ICI Pakistan Limited (as the '**Purchaser**') and each of Wyeth, Pfizer Pakistan Limited, Pfizer Inc., and Wyeth LLC (as '**Sellers**') have entered into the Asset Purchase Agreements each dated as of May 19, 2017, recording terms and conditions for the proposed sale of the Assets by the Sellers and its acquisition by the Purchaser (**APAs**), at an aggregate purchase price of PKR 1.91 billion (of which PKR 1.68 billion is attributable to Wyeth Pakistan Limited). The completion of the transaction contemplated in the APAs will remain subject to satisfaction of conditions precedent and regulatory and shareholders approvals specified therein.

The Company has duly caused this form / statement to be signed on its behalf by the undersigned hereunto duly authorized.

Sincerely,



S. M. Wajeehuddin
Director